We are live on ! Find out more
RAPP

Rapport Therapeutics
RAPP

55 hedge funds and large institutions have $582M invested in Rapport Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 10

57% more funds holding

Funds holding: 35 → 55 (+20)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

3.29% more ownership

Funds ownership: 74.47% → 77.76% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2% less capital invested

Capital invested by funds: $593M → $582M (-$11.6M)

Holders
55
Holders Change
+20
Holders Change %
+57.14%
% of All Funds
0.79%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
30
Increased
11
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$26.8M
2
BlackRock
BlackRock
New York
+$12.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$9.39M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.34M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$8.14M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.73M
3
Millennium Management
Millennium Management
New York
-$2.72M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.26M
5
SVCM
Saturn V Capital Management
Texas
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
MS
26
Maven Securities
Jersey
$613K +$643K +29,930 New
Morgan Stanley
27
Morgan Stanley
New York
$496K +$521K +24,228 New
WG
28
Winton Group
United Kingdom
$494K +$518K +24,127 New
LP
29
LMR Partners
United Kingdom
$410K -$645K -30,000 -60%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$409K +$429K +19,970 New
Bank of America
31
Bank of America
North Carolina
$391K +$411K +19,110 New
ACP
32
Acuta Capital Partners
California
$360K -$51.6K -2,400 -12%
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$324K +$340K +15,843 New
Barclays
34
Barclays
United Kingdom
$263K +$74.4K +3,463 +37%
Citigroup
35
Citigroup
New York
$262K +$274K +12,774 New
N
36
Nuveen
North Carolina
$247K +$259K +12,068 New
MIM
37
MetLife Investment Management
New Jersey
$117K +$123K +5,710 New
UBS Group
38
UBS Group
Switzerland
$114K +$52.2K +2,430 +78%
Mirae Asset Global ETFs Holdings
39
Mirae Asset Global ETFs Holdings
Hong Kong
$104K +$109K +5,077 New
SIM
40
Sandia Investment Management
Massachusetts
$102K – – –
CF
41
Corebridge Financial
Texas
$102K +$107K +4,967 New
SG Americas Securities
42
SG Americas Securities
New York
$101K +$106K +4,934 New
JP Morgan Chase
43
JP Morgan Chase
New York
$82.6K +$86.7K +4,033 New
Wells Fargo
44
Wells Fargo
California
$71.1K +$74.6K +3,472 New
SO
45
STRS Ohio
Ohio
$34.8K +$36.5K +1,700 New
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$34.5K +$36.2K +1,684 New
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$31K +$26.8K +1,247 +554%
VFA
48
Values First Advisors
Tennessee
$30.9K +$32.4K +1,507 New
T
49
Tidemark
California
$22.3K – – –
AIP
50
Ameritas Investment Partners
Nebraska
$19.3K +$20.2K +941 New
1
2
3

RAPP Hedge Fund Activity: Q3 2024 in Review

55 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q3 2024, worth a combined $582M — down 1.9% from $593M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new RAPP positions and 10 closed out — a net gain of 20 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $26.8M. The largest seller was Artal Group, exiting entirely with an estimated $8.14M sold.

  • 55 institutional investors held Rapport Therapeutics (RAPP) as of Q3 2024, up from 35 in Q2 2024.
  • Funds reported $582M of Rapport Therapeutics stock for Q3 2024, down 1.9% quarter-over-quarter.
  • 30 funds opened new Rapport Therapeutics positions in Q3 2024 and 10 closed out, a net change of +20 holders.
  • The largest Rapport Therapeutics buyer in Q3 2024 was Goldman Sachs, an estimated $26.8M added.
  • The largest Rapport Therapeutics seller in Q3 2024 was Artal Group, an estimated $8.14M sold.

Based on aggregated 13F filings for Q3 2024.